Why the study?
Irregular wide QRS complex tachycardia without structural heart disease presents diagnostic and therapeutic challenges, particularly in distinguishing atrial fibrillation in WPW syndrome from other arrhythmias.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
Intravenous procainamide successfully terminated atrial fibrillation in a hemodynamically stable patient with Wolff-Parkinson-White syndrome, avoiding contraindicated AV nodal blocking agents.
A 64-year-old female presented to the emergency room with persistent dizziness that began early that morning. She had a 30-year history of palpitations and known electrocardiogram (ECG) abnormalities. Her pulse was irregular at 130–270 min−1 and blood pressure was 90/40 mmHg. There were no other abnormalities on physical examination. A chest X-ray was normal and without cardiomegaly. Echocardiography revealed normal left ventricular contraction without structural abnormalities. Blood chemistry evaluation, including electrolytes and cardiac enzymes, was within normal limits. Twelve-lead ECG showed irregular wide QRS tachycardia of various configurations (Fig. 1). Twelve-lead ECG during tachycardia in the emergency room. How would you diagnose her tachycardia? The patient's ECG shows wide QRS tachycardia with a rate from 150 to 300 beats/min. The RR intervals are irregularly irregular and no P wave preceding QRS was confirmed. The QRS complex has beat–beat variations in morphology. At this point, some of the arrhythmias that should be considered are: (1) irregular ventricular tachycardia (such as torsades des pointes or polymorphic ventricular tachycardia); (2) atrial fibrillation (AF) with bundle branch block; (3) AF in Wolff–Parkinson–White (WPW) syndrome (pseudo-ventricular tachycardia). The QRS complex shows right axis deviation during tachycardia with no progressive change in cardiac axis, thus polymorphic ventricular tachycardia and torsades des pointes associated with QT prolongation are excluded. Polymorphic ventricular tachycardia associated electrolyte abnormality and myocardial ischemia could not be totally excluded by this ECG, however laboratory examination did not indicate myocardial ischemia or an electrolyte abnormality. The representative arrhythmia of the patient's irregular heart rate is AF, which is the most common cardiac arrhythmia. When the ventricular rate is slow, AF can be easily diagnosed. However if the ventricular rate is rapid, AF is difficult to appreciate because QRS complexes are clustered together and fibrillatory waves become more difficult to evaluate. The QRS complexes during AF with bundle branch block usually do not have beat–beat variation, and both an Rr′ pattern in lead V1 and R<S amplitude in V6 are uncommon for the ECG of right bundle branch block. On the other hand, the QRS complexes during AF in WPW syndrome are extremely bizarre and broad because the QRS complex reflects varying degrees of fusion of ventricular activation via the atrioventricular (AV) node and accessory pathways. To terminate AF and block the accessory pathway, procainamide was given intravenously at a dose of 400 mg over 30 min. It is important to note that AV nodal blocking agents are contraindicated in treatment of AF in patients with WPW syndrome. AV nodal blocking agents, for example verapamil and digoxin, decrease the number of impulses conducted through the His–Purkinje system and enhance conduction across accessory pathways, thus increasing the ventricular rate during AF. If the patient is hemodynamically unstable, electrical cardioversion should be performed. After infusion of procainamide, this patient's AF converted to normal sinus rhythm (Fig. 2) that included a short PR interval and a delta wave. A positive delta wave and QRS in V1 indicated a left sided accessory pathway. Twelve-lead ECG during sinus rhythm after infusion of procainamide. AF is the most serious arrhythmia associated with WPW syndrome. This arrhythmia has the possibility of degenerating into ventricular fibrillation, which can cause sudden cardiac death. Although the occurrence of ventricular fibrillation is rare, even among symptomatic patients with WPW syndrome, AF carries the potential for sudden cardiac death. The risk of sudden cardiac death in patients with WPW syndrome is related to the short effective refractory period of the anterograde accessory pathway. Electrophysiological studies are performed to measure the refractory period of the accessory pathway. Patients with an accessory pathway with an effective refractory period of less than 250 ms, as measured by an R–R interval between 2 preexcited complexes of <250 ms during AF, are defined as high risk. This patient's shortest R–R interval on ECG was about 200 ms (300 bpm), which indicated high risk of sudden cardiac death. The patient underwent catheter ablation. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias [1], which include accessory pathway-mediated arrhythmias, recommend catheter ablation for long-term therapy in patients with symptomatic WPW syndrome (Class I). The classic preexcitation syndrome was described by Wolff, Parkinson, and White in 1930 as an ECG demonstrating bundle branch block with short P–R interval. With advances in clinical electrophysiological study, this syndrome is currently proposed to be due to preexcitation of the ventricle by an accessory pathway(s). The prevalence of WPW syndrome has been estimated to be 0.1–0.3% in the general population [2]. The most important clinical consequence of WPW syndrome is supraventricular tachycardia consisting of AV reciprocating tachycardia (AVRT). During orthodromic AVRT, the impulse is conducted from atrium to ventricle across the AV node, resulting in narrow QRS complex. Conversely, during antidromic AVRT, the impulse is conducted from atrium to ventricle across the accessory pathway, resulting in wide QRS complexes. Occasionally, patients with AVRT develop AF that may lead to hemodynamic deterioration owing to anterograde conduction over the accessory pathway. The incidence of AF in patients with WPW syndrome is reported to be 10–30% [3]-[5]. No relationship between the onset of AF and localization of accessory pathways has been reported [6], and successful ablation of the accessory pathway prevents the recurrence of AF in the majority of patients. It is known that an accessory pathway is associated with AF, but this mechanism has not been clarified. Recently, a potential role of the pulmonary veins in the development of AF in patients with WPW syndrome was reported [7]. In Japan and some European countries, AF in WPW syndrome is generally referred as pseudo-ventricular tachycardia. However, this term is rarely used in the United States because it may lead physicians to misinterpret the mechanism of the arrhythmia. None.
No takes yet. Share an insight, caveat, or question.
Kobayashi et al. (2012) conducted a case report in Atrial fibrillation in Wolff-Parkinson-White (WPW) syndrome (n=1). Intravenous procainamide was evaluated on Conversion to normal sinus rhythm.
Synapse has enriched 10 related papers. Consider them for comparative context: